<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Br J Pharmacol</journal-id>
<journal-id journal-id-type="iso-abbrev">Br. J. Pharmacol</journal-id>
<journal-id journal-id-type="doi">10.1111/(ISSN)1476-5381</journal-id>
<journal-id journal-id-type="publisher-id">BPH</journal-id>
<journal-title-group>
<journal-title>British Journal of Pharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0007-1188</issn>
<issn pub-type="epub">1476-5381</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26220736</article-id>
<article-id pub-id-type="pmc">4621986</article-id>
<article-id pub-id-type="doi">10.1111/bph.13259</article-id>
<article-id pub-id-type="publisher-id">BPH13259</article-id>
<article-id pub-id-type="other">2015-BJP-0268-RP.R1</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Research Paper</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Research Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Addition of a single methyl group to a small molecule sodium channel inhibitor introduces a new mode of gating modulation</article-title>
<alt-title alt-title-type="right-running-head">Multiple modes of Nav channel modulation by PF‐06526290</alt-title>
<alt-title alt-title-type="left-running-head">L Wang et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="bph13259-cr-0001">
<name>
<surname>Wang</surname>
<given-names>Lingxin</given-names>
</name>
<xref ref-type="aff" rid="bph13259-aff-0001">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13259-cr-0002">
<name>
<surname>Zellmer</surname>
<given-names>Shannon G.</given-names>
</name>
<xref ref-type="aff" rid="bph13259-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="bph13259-cr-0003">
<name>
<surname>Printzenhoff</surname>
<given-names>David M.</given-names>
</name>
<xref ref-type="aff" rid="bph13259-aff-0002">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="bph13259-cr-0004">
<name>
<surname>Castle</surname>
<given-names>Neil A.</given-names>
</name>
<xref ref-type="aff" rid="bph13259-aff-0002">
<sup>2</sup>
</xref>
</contrib>
</contrib-group>
<aff id="bph13259-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Glaxo SmithKline</named-content>
<named-content content-type="city">Shanghai</named-content>
<country country="US">China</country>
</aff>
<aff id="bph13259-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Icagen Inc.</named-content>
<named-content content-type="city">Durham</named-content>
<named-content content-type="country-part">NC</named-content>
<country country="US">USA</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label>
Correspondence<break></break>
Neil A. Castle, Icagen Inc, 4222 Emperor Boulevard, Durham, NC 27703, USA. E‐mail: <email>ncastle@icagen.com</email><break></break></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>10</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="ppub">
<month>10</month>
<year>2015</year>
</pub-date>
<volume>172</volume>
<issue>20</issue>
<issue-id pub-id-type="doi">10.1111/bph.2015.172.issue-20</issue-id>
<fpage>4905</fpage>
<lpage>4918</lpage>
<history>
<date date-type="received">
<day>10</day>
<month>3</month>
<year>2015</year>
</date>
<date date-type="rev-recd">
<day>17</day>
<month>6</month>
<year>2015</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>7</month>
<year>2015</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2015 The British Pharmacological Society <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2015 The British Pharmacological Society</copyright-statement>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BPH-172-4905.pdf" xlink:type="simple"></self-uri>
<abstract abstract-type="main">
<sec id="bph13259-sec-0001">
<title>Background and Purpose</title>
<p>Aryl sulfonamide Na<sub>v</sub>1.3 or Na<sub>v</sub>1.7 voltage‐gated sodium (Na<sub>v</sub>) channel inhibitors interact with the Domain 4 voltage sensor domain (D4 VSD). During studies to better understand the structure‐activity relationship of this interaction, an additional mode of channel modulation, specifically slowing of inactivation, was revealed by addition of a single methyl moiety. The objective of the current study was to determine if these different modulatory effects are mediated by the same or distinct interactions with the channel.</p>
</sec>
<sec id="bph13259-sec-0002">
<title>Experimental Approach</title>
<p>Electrophysiology and site‐directed mutation were used to compare the effects of PF‐06526290 and its desmethyl analogue PF‐05661014 on Na<sub>v</sub> channel function.</p>
</sec>
<sec id="bph13259-sec-0003">
<title>Key Results</title>
<p>PF‐05661014 selectively inhibits Na<sub>v</sub>1.3 versus Na<sub>v</sub>1.7 currents by stabilizing inactivated channels via interaction with D4 VSD. In contrast, PF‐06526290, which differs from PF‐05661014 by a single methyl group, exhibits a dual effect. It greatly slows inactivation of Na<sub>v</sub> channels in a subtype‐independent manner. However, upon prolonged depolarization to induce inactivation, PF‐06526290 becomes a Na<sub>v</sub> subtype selective inhibitor similar to PF‐05661014. Mutation of the D4 VSD modulates inhibition of Na<sub>v</sub>1.3 or Na<sub>v</sub>1.7 by both PF‐05661014 and PF‐06526290, but has no effect on the inactivation slowing produced by PF‐06526290. This finding, along with the absence of functional inhibition of PF‐06526290‐induced inactivation slowing by PF‐05661014, suggests that distinct interactions underlie the two modes of Na<sub>v</sub> channel modulation.</p>
</sec>
<sec id="bph13259-sec-0004">
<title>Conclusions and Implications</title>
<p>Addition of a methyl group to a Na<sub>v</sub> channel inhibitor introduces an additional mode of gating modulation, implying that a single compound can affect sodium channel function in multiple ways.</p>
</sec>
</abstract>
<counts>
<page-count count="14"></page-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>bph13259</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>October 2015</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.6.9 mode:remove_FC converted:04.11.2015</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="bph13259-cit-0000" publication-type="journal">
<string-name>
<surname>Wang</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Zellmer</surname>, <given-names>S. G.</given-names>
</string-name>, <string-name>
<surname>Printzenhoff</surname>, <given-names>D. M.</given-names>
</string-name>, and <string-name>
<surname>Castle</surname>, <given-names>N. A.</given-names>
</string-name> (<year>2015</year>) <article-title>Addition of a single methyl group to a small molecule sodium channel inhibitor introduces a new mode of gating modulation</article-title>. <source/>British Journal of Pharmacology, <volume>172</volume>: <fpage>4905</fpage>–<lpage>4918</lpage>. doi: <ext-link ext-link-type="doi" xlink:href="10.1111/bph.13259">10.1111/bph.13259</ext-link>.<pub-id pub-id-type="pmid">26220736</pub-id></mixed-citation>
</p>
</notes>
</front>
</article>
</pmc-articleset>